Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. (PAVM) reports on events occurring on November 22, 2024, regarding its subsidiary, Lucid Diagnostics Inc. ("Lucid"). The filing details the closing of a private placement transaction involving senior secured convertible notes.
Key Financial Metrics
- Debt Issuance: Lucid sold $21.95 million in principal amount of Senior Secured Convertible Notes (Lucid 2024 Convertible Notes).
- Gross Proceeds: $21.95 million.
- Net Proceeds: $18.3 million after repayment of prior debt.
- Debt Repayment: A portion of the proceeds was used to fully repay the "Lucid 2023 Convertible Note."
- Liquidity Impact: The transaction resulted in a net cash inflow of $18.3 million to Lucid.
Material Changes
The primary material change is the refinancing of Lucid's debt structure. The company replaced its existing Senior Convertible Note (issued in March 2023) with new Senior Secured Convertible Notes. This transaction altered the company's direct financial obligations and security arrangements, introducing new agreements including a Registration Rights Agreement, a Guaranty, and a Security and Pledge Agreement.
Outlook, Risks, and Unusual Items
Management Commentary: The filing confirms the successful closing of the transaction pursuant to a Securities Purchase Agreement dated November 12, 2024. The company notes that the new notes are secured and include specific covenants and risk allocations detailed in the attached exhibits.
Risks and Contingencies: The filing explicitly states that the representations, warranties, and covenants in the new agreements are made solely for the benefit of the parties to those agreements and for the allocation of risk between them. These terms may not reflect the current factual status of the company outside the context of the specific agreements.
Unusual Items: The transaction involves a private placement to accredited investors and the creation of a direct financial obligation secured by a pledge agreement.
Investor Verification Checklist
- Verify the specific interest rate, maturity date, and conversion terms of the Lucid 2024 Convertible Notes in Exhibit 4.1.
- Review the Security and Pledge Agreement (Exhibit 10.4) to understand the specific assets pledged as collateral.
- Confirm the exact principal amount of the repaid Lucid 2023 Convertible Note to reconcile the $3.65 million difference between gross and net proceeds.
- Examine the Registration Rights Agreement (Exhibit 10.2) for potential dilution impacts on existing shareholders.
- Check subsequent filings for any amendments to the terms described in the November 12, 2024 Securities Purchase Agreement.